Navigation Links
Study finds natural compound can be used for 3-D printing of medical implants
Date:10/23/2013

Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and Laser Zentrum Hannover have discovered that a naturally-occurring compound can be incorporated into three-dimensional (3-D) printing processes to create medical implants out of non-toxic polymers. The compound is riboflavin, which is better known as vitamin B2.

"This opens the door to a much wider range of biocompatible implant materials, which can be used to develop customized implant designs using 3-D printing technology," says Dr. Roger Narayan, senior author of a paper describing the work and a professor in the joint biomedical engineering department at NC State and UNC-Chapel Hill.

The researchers in this study focused on a 3-D printing technique called two-photon polymerization, because this technique can be used to create small objects with detailed features such as scaffolds for tissue engineering, microneedles or other implantable drug-delivery devices.

Two-photon polymerization is a 3-D printing technique for making small-scale solid structures from many types of photoreactive liquid precursors. The liquid precursors contain chemicals that react to light, turning the liquid into a solid polymer. By exposing the liquid precursor to targeted amounts of light, the technique allows users to "print" 3-D objects.

Two-photon polymerization has its drawbacks, however. Most chemicals mixed into the precursors to make them photoreactive are also toxic, which could be problematic if the structures are used in a medical implant or are in direct contact with the body.

But now researchers have determined that riboflavin can be mixed with a precursor material to make it photoreactive. And riboflavin is both nontoxic and biocompatible it's a vitamin found in everything from asparagus to cottage cheese.


'/>"/>

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University
Source:Eurekalert  

Page: 1

Related biology news :

1. Clemson University study points to possible treatment for brain disorders
2. Study: Death by moonlight? Not always
3. UMass Amherst physics professor wins grant to study organization inside cells space
4. Poorly camouflaged insects can kick off a cascade of ecological impacts, new CU-Boulder study finds
5. In Nepal, villagers land uses help people and tigers, study finds
6. Study explores the role of uncertainty in infectious disease modelling
7. Clean living is a luxury wild animals cant afford, study suggests
8. Study puts freshwater biodiversity on the map for planners and policymakers
9. What makes us left or right handed? New study rules out strong genetic factors
10. Study: Acidity can change cell membrane properties
11. Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study finds natural compound can be used for 3-D printing of medical implants
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
Breaking Biology Technology: